Tag: SNY

Sanofi THOR-707 and Merck Keytruda to be evaluated for cancer combotherapy

Sanofi () has entered into an agreement with Merck () to conduct a Phase 2 clinical trial to evaluate the safety, pharmacokinetics, and preliminary efficacy of THOR-707, a highly differentiated non-alpha IL-2 candidate with a best-in-class profile, combined with or in sequenced administration with MSD’s KEYTRUDA (pembrolizumab) in patients with various cancers.
Show more
Show less

Under the agreement, Sanofi will sponsor the clinical trials while MSD will provide KEYTRUDA. 

THOR-707 is currently being evaluated by Sanofi in an ongoing Phase 1 open-label, multi-center, dose escalation and expansion trial.  This study is designed to evaluate the safety and tolerability of THOR-707, and to determine its recommended Phase 2 dose alone and in combination with anti-PD-1 and anti-EGFR antibodies. 

In addition to testing THOR-707 in combination with KEYTRUDA, Sanofi is separately evaluating the activity of this novel biologic in combination with other anti-PD-1 antibodies, including Libtayo® (cemiplimab-rwlc) and with anti-EGFR and anti-CD38 antibodies for various types of cancer tumors. 

THOR-707 demonstrated in preclinical studies the ability to induce the expansion of CD8+T-cells resulting in anti-tumor effects both as single agent as well as in combination with an anti-PD1 mAb.

It is the first molecule from the Synthorin platform, Sanofi’s unique expanded genetic alphabet platform, which has the potential to create a new generation of precision medicines for oncology and autoimmune disease. 

Press release

Sanofi to develop dupilumab in type 2 inflammatory diseases

In line with their December 2019 announcement, Sanofi () expects to achieve over €10 billion in peak sales of Dupixent (dupilumab) targeting additional clinical uses in diseases driven by type 2 inflammation including Eosinophilic Esophagitis and a subset of Chronic Obstructive Pulmonary Disease.
Show more
Show less

Sanofi executives will provide an overview of the growth and development strategy for Dupixent (dupilumab) in the third of its five-part series to highlight Sanofi’s progress. Sanofi co-develops and co-commercializes Dupixent with Regeneron ().

The company is targeting the below additional indications. 

  • Eosinophilic Esophagitis (EoE)
  • Chronic Obstructive Pulmonary Disease (COPD) with Evidence of Type 2 Inflammation
  • Prurigo Nodularis (PN)
  • Chronic Spontaneous Urticaria (CSU)
  • Bullous Pemphigoid (BP)

All of these potential uses are investigational, and the safety and efficacy of Dupixent in any of these indications has not been evaluated yet.

While additional data contribute to the growing body of evidence demonstrating Dupixent’s best in class safety profile combined with strong efficacy benefit for atopic dermatitis and further validate it as a standard of care treatment for asthma; Dupixent’s unique mechanism of action simultaneously inhibits IL-4 and IL-13, which play a key role in type 2 inflammation in multiple diseases. 

Sanofi press release